New research from the Mayo Clinic shows promising results for a noninvasive methylated DNA marker panel that could reduce the number of unnecessary and painful biopsies in patients with abnormal uterine bleeding.
Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.
Pregnant women with higher intakes of calcium and zinc before conceiving were significantly less likely to suffer from hypertensive disorders during pregnancy, highlighting the importance of preconception nutrition in reducing pregnancy complications. - Research presented at NUTRITION 2024
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The researchers found that invasive urodynamic testing did not improve outcomes or cost-effectiveness in women with refractory overactive bladder symptoms.
New research found that first-time mothers experienced substantial sleep disruption for more than 3 months after childbirth, even as total sleep time gradually recovered.
New data from two international studies reveal breastfeeding after breast cancer, even for women with BRCA mutations, does not increase the risk of recurrence.
Nocturnal hot flashes are more frequent after midnight, with more than half occurring in the second half of the night, potentially disrupting REM sleep and contributing to heightened cardiovascular disease risk in perimenopausal women.